In brief
- A European drug-checking service in Zurich identified a sample sold as hashish containing zero THC, but laced with two synthetic cannabinoids: MDMB-4en-PINACA and ADB-4en-PINACA.
- The finding is part of PRO Test’s weekly bulletin, which compiles results from drug-checking services across multiple European countries and has also noted an uptick in lesser-known designer benzodiazepines.
- Synthetic cannabinoids cannot be identified by sight or smell, and their safety margin between an active dose and a toxic dose is significantly narrower than that of THC.
A sample purchased as hashish in Zurich and submitted for drug checking contained no cannabis at all. The results, published in late August by European drug-checking service PRO Test, revealed two synthetic cannabinoids—MDMB-4en-PINACA and ADB-4en-PINACA—sprayed onto an inert plant base, without a single detectable milligram of THC.
A weekly monitor tracking what is actually circulating
Run by the Polish firm Chemical Safety, PRO Test publishes a weekly summary of test results from samples submitted across several countries—including Austria, France, Slovenia, Spain, and Switzerland in that week’s report—alongside data shared by other drug-checking services across the continent. This is neither an academic study nor an official government alert; it is a real-world snapshot of the street market, sourced directly from laboratories analyzing what people have actually purchased.
That same bulletin highlighted another trend that has been building for months: three of the top ten substances queried by users were novel designer benzodiazepines that were barely on the radar a year ago—ethylbromazolam, bromonordiazolam, and flubrotizolam—while a sample sold as alprazolam in Austria turned out to be flualprazolam. These compounds are synthesized to skirt the legal controls placed on traditional benzodiazepines, and their pharmacology remains largely unstudied.
Why synthetic hash is different
Synthetic cannabinoids like MDMB-4en-PINACA were developed to activate the same cannabinoid receptors as THC, but they are cheap to manufacture and dozens of times more potent at the receptor site. That makes them a lucrative adulterant: a few grams sprayed over cheap plant matter yield a product that looks like hash, smells like hash, and sells like hash, yet carries effects that are far harder to predict. The margin between an active dose and one that triggers tachycardia, severe anxiety, or loss of consciousness is dramatically narrower than with natural cannabis—and it varies widely from batch to batch because spraying is never uniform.
For consumers, there is no visual warning sign: the appearance can be indistinguishable from genuine hash. At-home colorimetric test kits for cannabis are calibrated for THC and cannot identify these synthetic compounds; at best, they offer indirect clues and are never a substitute for laboratory testing.
What this means
This is neither an isolated incident nor the first: adulterating low-grade cannabis and hash with synthetic cannabinoids has been documented across Europe for years—recently seen in Spain with products sold as CBD—and this Swiss sample confirms the issue remains ongoing. The sensible response is neither panic nor harsher crackdowns, but the core tenets of harm reduction: sourcing from trusted channels, being wary of unusually cheap hash or odd textures, and testing whenever possible through drug-checking services or field test kits. This form of decentralized surveillance—consumers submitting samples and testing services reporting their findings week after week—is currently the fastest way to track what is actually circulating, long before official health agencies issue warnings. Readers interested in exploring the broader drug landscape can consult Psiconáutica’s Psychedelics Guide.
Source
- PRO Test (Chemical Safety sp. z o.o.). Drug Purity Report: Week 34, 2026. PRO Test, August 30, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
